Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 58

Sort by

Sort Order Select

Journal Articles

Synergistic efficacy of the dual PI3K-δ/γ inhibitor duvelisib with the Bcl-2 inhibitor venetoclax in Richter syndrome PDX models

Andrea Iannello, Nicoletta Vitale, Silvia Coma, Francesca Arruga, Amy Chadburn, Arianna Di Napoli, Carlo Laudanna, John N. Allan, Richard R. Furman, Jonathan A. Pachter, Silvia Deaglio, Tiziana Vaisitti

Blood (2021) 137 (24): 3378–3389.

https://doi.org/10.1182/blood.2020010187

Published: 2021

Includes: Supplemental data

Journal Articles

Imbalance in T Cell Subsets Triggers the Autoimmune Toxicity of PI3K Inhibitors in CLL

Deepti Gadi, PhD, Siddha Kasar, PhD, Alec Griffith, BS, Pui Yan Chiu, Svitlana Tyekucheva, PhD, Vanessa Rai, BS, Alexander R. Vartanov, MD, Stacey M. Fernandes, BS, Yang Pan, PhD, James A Lederer, PhD, Barbara Sherry, PhD, Jennifer R. Brown, MD PhD

Blood (2019) 134 (Supplement_1): 1745.

https://doi.org/10.1182/blood-2019-122961

Published: 2019

Journal Articles

Dose Optimization of Duvelisib in Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma from the Phase 2 Primo Trial: Selection of Regimen for the Dose-Expansion Phase

Steven M. Horwitz, MD, Neha Mehta-Shah, MD, Barbara Pro, MD, Eric D Jacobsen, MD, Carla Casulo, Jonathan E. Brammer, MD, Jeff Haney, Hagop Youssoufian, MD, David T. Weaver, PhD, Michael Baglio, PharmD, Jasminder Soto, Narayana Narasimhan, Jasmine Zain, MD

Blood (2019) 134 (Supplement_1): 1567.

https://doi.org/10.1182/blood-2019-121401

Published: 2019

Journal Articles

A Phase I Study of Duvelisib and Venetoclax in Patients with Relapsed or Refractory CLL / SLL

Jennifer L. Crombie, MD, Svitlana Tyekucheva, PhD, Alexandra Savell, BS, Karen Francoeur, RN, Mark Choiniere, BA, Josie Montegaard, NP, Jacob D. Soumerai, MD, Jon E. Arnason, MD, David C. Fisher, MD, Jennifer R. Brown, MD PhD, Matthew S. Davids, MD

Blood (2019) 134 (Supplement_1): 1763.

https://doi.org/10.1182/blood-2019-127343

Published: 2019

Journal Articles

The Dual PI3K-δ/γ Inhibitor Duvelisib in Combination with the Bcl-2 Inhibitor Venetoclax Shows Promising Responses in Richter Syndrome-PDX Models

Andrea Iannello, PhD, Francesca Arruga, PhD, Nicoletta Vitale, PhD, Elisa Marchi, Richard R. Furman, MD, John N. Allan, MD, Silvia Coma, PhD, Jonathan A. Pachter, PhD, Silvia Deaglio, MD PhD, Tiziana Vaisitti, PhD

Blood (2019) 134 (Supplement_1): 2862.

https://doi.org/10.1182/blood-2019-125754

Published: 2019

Journal Articles

Discontinuation Patterns in Patients Receiving Novel Oral Agents for Chronic Lymphocytic Leukemia in the Veterans Health Administration

Hsu-Chih Chien, PhD MSc, Vikas Patil, MS, Kelli M Rasmussen, MS, Christina Yong, MA, Juliana M L Biondo, MD, Mary Halloran, PharmD, BCPS, Sheila Shapouri, PharmD, MS, Mei Wu, PharmD, Zachary R Burningham, PhD, Brian C Sauer, PhD, Ahmad S Halwani, MD

Blood (2019) 134 (Supplement_1): 4309.

https://doi.org/10.1182/blood-2019-128645

Published: 2019

Journal Articles

Cytogenetic and Molecular Marker Associations to Outcomes with Duvelisib and Ofatumumab Treatment in Patients with Relapsed or Refractory CLL/SLL in the DUO Trial

Jennifer R Brown, MD PhD, Kam Sprott, PhD, Santosh Reddy, Stephanie Lustgarten, PhD, David T. Weaver, PhD, Alexey Danilov, MD PhD

Blood (2019) 134 (Supplement_1): 4312.

https://doi.org/10.1182/blood-2019-122491

Published: 2019

Journal Articles

Comparative Outcomes of Relapsed Follicular Lymphoma Patients Treated with Novel Agents: A Multi-Center Analysis

Blood (2019) 134 (Supplement_1): 3982.

https://doi.org/10.1182/blood-2019-124783

Published: 2019

Journal Articles

Rapid and Durable Responses with the SYK/JAK Inhibitor Cerdulatinib in a Phase 2 Study in Relapsed/Refractory Follicular Lymphoma-Alone or in Combination with Rituximab

Stephen D. Smith, MD, Javier Munoz, MD MS, FACP, Don Stevens, MD, Sonali M. Smith, MD, Tatyana A. Feldman, MD, J Christine Ye, MDMSc, Sven de Vos, MD PhD, Brian T. Hess, MD, Carole B. Miller, MD, James L. Khatcheressian, MD, Matt R. Birrell, Janet M. Leeds, PhD, Gregory P. Coffey, PhD, Pamela B. Conley, PhD, Glenn C. Michelson, MD, John T. Curnutte, MD PhD, Paul A. Hamlin, MD

Blood (2019) 134 (Supplement_1): 3981.

https://doi.org/10.1182/blood-2019-124231

Published: 2019

Journal Articles

Ex Vivo Drug Sensitivity Screens Identify Personalized Treatment Options for CLL Patients

Sigrid Strand Skånland, PhD, Bendiksen Henrik, MSc, Andrea Cremaschi, PhD, Deepak Balaji Thimiri Govinda Raj, PhD, Ludvig Andre Munthe, MD PhD, Geir Erland Tjønnfjord, MD PhD, Kjetil Taskén, MD PhD

Blood (2019) 134 (Supplement_1): 5446.

https://doi.org/10.1182/blood-2019-121890

Published: 2019

Journal Articles

Efficacy of Phosphatidylinositol 3-Kinase (PI3K) Inhibitors in Patients with Relapsed and Refractory Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphoma

Anita Sultan, MD, Bradley J. Grant, JD, Donald P. Quick, MD, Chandler Graf, Sriman Swarup, MDMBBS, Sriman Swarup, MDMBBS, Jonathan Kopel, BS, Thura Win Htut, MBBS, MRCP, Somedeb Ball, MD, Ei Moe Phyu, MD, Myat Min Han, MD, Yin Mon Myat, MD, Nicholas D'Cunha, MD, Myint Aung Win, MDMBBS, Kyaw Zin Thein, MDMBBS

Blood (2019) 134 (Supplement_1): 5480.

https://doi.org/10.1182/blood-2019-123231

Published: 2019

Journal Articles

Risk of Serious Adverse Events, Infection and Sepsis in Patients with Relapsed and Refractory Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphoma Treated with Idelalisib

Jonathan Kopel, BS, Sriman Swarup, MDMBBS, Anita Sultan, MD, Lukman Tijani, MD, Ei Moe Phyu, MD, Myint Aung Win, MDMBBS, Thura Win Htut, MBBS, MRCP, Ye Aung, Akshar Dash, Myat Min Han, MD, Yin Mon Myat, MD, Donald P. Quick, MD, Nicholas D'Cunha, MD, Kyaw Zin Thein, MDMBBS

Blood (2019) 134 (Supplement_1): 5489.

https://doi.org/10.1182/blood-2019-123179

Published: 2019

Journal Articles

A Phase 2, Randomized, Open-Label, 2-Arm Study Comparing 2 Intermittent Dosing Schedules of Duvelisib in Patients with Indolent Non-Hodgkin Lymphoma (iNHL) (TEMPO)

Reem Karmali, MD, Hagop Youssoufian, MD, Kam Sprott, PhD, David T. Weaver, PhD, Narayana Narasimhan, Stephanie Lustgarten, PhD, Gloria Patrick, Alena Zalutskaya, Leo I. Gordon, MD

Blood (2019) 134 (Supplement_1): 5251.

https://doi.org/10.1182/blood-2019-124406

Published: 2019

Journal Articles

Phosphatidylinositol 3-Kinase (PI3K) Inhibitors-Related Hematological Toxicities in Patients with Relapsed and Refractory Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphoma

Bradley J. Grant, JD, Anita Sultan, MD, Nicholas D'Cunha, MD, Chandler Graf, Sriman Swarup, MDMBBS, Myint Aung Win, MDMBBS, Ei Moe Phyu, MD, Thura Win Htut, MBBS, MRCP, Myat Min Han, MD, Yin Mon Myat, MD, Nimesh Adhikari, MD, Nyein Htway Yu, MBBS, MD, Donald P. Quick, MD, Kyaw Zin Thein, MDMBBS

Blood (2019) 134 (Supplement_1): 5877.

https://doi.org/10.1182/blood-2019-123531

Published: 2019

Journal Articles

Identification of Genotype-Specific Therapeutic Vulnerabilities By Comparative Dynamic BH3 Profiling Analysis of Human and Murine CLL

Shanye Yin, PhD, Salma Parvin, PhD, Elisa Ten Hacken, PhD, Rebecca Valentin, MD, Heather Joyal, Laura Z. Rassenti, PhD, Emanuela M. Ghia, PhD, Thomas J. Kipps, MD PhD, Donna S Neuberg, ScD, Lili Wang, MD PhD, Matthew S. Davids, MD, Ruben D. Carrasco, MD PhD, Anthony G. Letai, MD PhD, Catherine J. Wu, MD

Blood (2019) 134 (Supplement_1): 4281.

https://doi.org/10.1182/blood-2019-127293

Published: 2019

Journal Articles

Incidence of Serious Adverse Events, Pneumonitis, Infection and Sepsis in Patients with Relapsed and Refractory Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphoma Treated with Phosphatidylinositol 3-Kinase (PI3K) Inhibitors

Sriman Swarup, MDMBBS, Donald P. Quick, MD, Anita Sultan, MD, Myint Aung Win, MDMBBS, Ei Moe Phyu, MD, Thura Win Htut, MBBS, MRCP, Sariya Wongsaengsak, MD, Myet Mon Zin, MD, Myat Min Han, MD, Yin Mon Myat, MD, Sanjay Awasthi, MD, Lukman Tijani, MD, Kyaw Zin Thein, MDMBBS

Blood (2019) 134 (Supplement_1): 798.

https://doi.org/10.1182/blood-2019-123177

Published: 2019

Journal Articles

Duvelisib for CLL/SLL and follicular non-Hodgkin lymphoma

Krish Patel, Alexey V. Danilov, John M. Pagel

Blood (2019) 134 (19): 1573–1577.

https://doi.org/10.1182/blood.2019001795

Published: 2019

Journal Articles

DUO delivers for duvelisib

Jennifer R. Brown

Blood (2018) 132 (23): 2422–2424.

https://doi.org/10.1182/blood-2018-10-879650

Published: 2018

Journal Articles

The phase 3 DUO trial: duvelisib vs ofatumumab in relapsed and refractory CLL/SLL

Blood (2018) 132 (23): 2446–2455.

https://doi.org/10.1182/blood-2018-05-850461

Published: 2018

Includes: Supplemental data

Journal Articles

The Influence of the Bone Marrow Niche on Drug Response Phenotypes of Blood Cancers

Sophie Rabe, MSc, Eva Schitter, Tobias Roider, Peter-Martin Bruch, Carolin Kolb, Marta Stolarczyk, Jennifer Hüllein, Junyan Lu, Christof von Kalle, Christoph Lutz, Peter Dreger, Carsten Mueller-Tidow, Thorsten Zenz, MD, Wolfgang Huber, Sascha Dietrich, MD

Blood (2018) 132 (Supplement 1): 262.

https://doi.org/10.1182/blood-2018-99-116053

Published: 2018

NARROW

Synergistic efficacy of the dual PI3K-δ/γ inhibitor duvelisib with the Bcl-2 inhibitor venetoclax in Richter syndrome PDX models

Imbalance in T Cell Subsets Triggers the Autoimmune Toxicity of PI3K Inhibitors in CLL

Dose Optimization of Duvelisib in Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma from the Phase 2 Primo Trial: Selection of Regimen for the Dose-Expansion Phase

A Phase I Study of Duvelisib and Venetoclax in Patients with Relapsed or Refractory CLL / SLL

The Dual PI3K-δ/γ Inhibitor Duvelisib in Combination with the Bcl-2 Inhibitor Venetoclax Shows Promising Responses in Richter Syndrome-PDX Models

Discontinuation Patterns in Patients Receiving Novel Oral Agents for Chronic Lymphocytic Leukemia in the Veterans Health Administration

Cytogenetic and Molecular Marker Associations to Outcomes with Duvelisib and Ofatumumab Treatment in Patients with Relapsed or Refractory CLL/SLL in the DUO Trial

Comparative Outcomes of Relapsed Follicular Lymphoma Patients Treated with Novel Agents: A Multi-Center Analysis

Rapid and Durable Responses with the SYK/JAK Inhibitor Cerdulatinib in a Phase 2 Study in Relapsed/Refractory Follicular Lymphoma-Alone or in Combination with Rituximab

Ex Vivo Drug Sensitivity Screens Identify Personalized Treatment Options for CLL Patients

Efficacy of Phosphatidylinositol 3-Kinase (PI3K) Inhibitors in Patients with Relapsed and Refractory Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphoma

Risk of Serious Adverse Events, Infection and Sepsis in Patients with Relapsed and Refractory Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphoma Treated with Idelalisib

A Phase 2, Randomized, Open-Label, 2-Arm Study Comparing 2 Intermittent Dosing Schedules of Duvelisib in Patients with Indolent Non-Hodgkin Lymphoma (iNHL) (TEMPO)

Phosphatidylinositol 3-Kinase (PI3K) Inhibitors-Related Hematological Toxicities in Patients with Relapsed and Refractory Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphoma

Identification of Genotype-Specific Therapeutic Vulnerabilities By Comparative Dynamic BH3 Profiling Analysis of Human and Murine CLL

Incidence of Serious Adverse Events, Pneumonitis, Infection and Sepsis in Patients with Relapsed and Refractory Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphoma Treated with Phosphatidylinositol 3-Kinase (PI3K) Inhibitors

Duvelisib for CLL/SLL and follicular non-Hodgkin lymphoma

DUO delivers for duvelisib

The phase 3 DUO trial: duvelisib vs ofatumumab in relapsed and refractory CLL/SLL

The Influence of the Bone Marrow Niche on Drug Response Phenotypes of Blood Cancers

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only